Key facts
- It has raised $510K across 1 recorded rounds; the latest was Seed Round ($293K) in Dec 2021.
- Notable investors include Virginia Innovation Partnership Corporation, Common Wealth Angels, Regional Accelerator & Mentoring Program.
- Chorda Pharma has filed 3 Form Ds with the SEC since 2022, most recently Dec 2024 ($200K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Chorda Pharma
Funding rounds
1 roundsAbout Chorda Pharma
Operator of a pharmaceutical company intended to treat arthritis, diabetic neuropathy, sports injuries, and other ailments requiring long-term treatment to relieve pain. The company's medications are opioid-free and are used as an alternative to traditional prescription-based pain relievers, like opioids, and provide a pipeline of proprietary analgesics for managing chronic pain, enabling patients to get treated without having to consume harmful drugs and pain relievers.
- Sector
- Healthcare
- HQ
- Roanoke, VA, United States
- Founded
- 2018
- Website
- chordapharma.com/
- Ownership
- Privately Held (backing)
Chorda Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chorda Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chorda Pharma in its N-PORT filings yet. We sweep new filings monthly.